234-OR: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with IGlarLixi vs. Premix 70/30 in the SoliMix Trial

Introduction: iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, offers an alternative treatment advancement option to premix insulin for uncontrolled basal insulin-treated T2D. SoliMix, an open-label, multicenter study, was the first to compare these two insulin coformulations. Methods: SoliMix randomized adults with T2D and HbA1c ≥7.5-≤10 % on basal insulin + oral antihyperglycemic drugs (OADs) to once-daily iGlarLixi or twice-daily premix insulin 70/30 analogue (BiAsp 70/30). Co-primary efficacy endpoints were non-inferiority in HbA1c reduction or superiority in bodyweight change from baseline to Week 26 of iGlarLixi vs. BiAsp 70/30. Results: Both co-primary efficacy endpoints were met (Table), as well as iGlarLixi superiority vs. BiAsp 70/30 in HbA1c reduction. Significantly more participants reached HbA1c